Skip to main content

Jim Cramer says to buy shares of Danaher on the dip

The life sciences and medical technology company beat earnings estimates in the third quarter but narrowed its 2022 bioprocessing revenue growth forecast.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.